Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Holly A Jensen"'
Autor:
Rodica P Bunaciu, Holly A Jensen, Robert J MacDonald, Dorian H LaTocha, Jeffrey D Varner, Andrew Yen
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135668 (2015)
6-Formylindolo(3,2-b)carbazole (FICZ) is a photoproduct of tryptophan and an endogenous high affinity ligand for aryl hydrocarbon receptor (AhR). It was previously reported that, in patient-derived HL-60 myeloblastic leukemia cells, retinoic acid (RA
Externí odkaz:
https://doaj.org/article/c267e7b9403b4af0a8609cf1e8354268
Autor:
Holly A Jensen, Rodica P Bunaciu, Christopher N Ibabao, Rebecca Myers, Jeffrey D Varner, Andrew Yen
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e98929 (2014)
Emergent resistance can be progressive and driven by global signaling aberrations. All-trans retinoic acid (RA) is the standard therapeutic agent for acute promyelocytic leukemia, but 10-20% of patients are not responsive, and initially responsive pa
Externí odkaz:
https://doaj.org/article/2b866f2ca5ff44e2bfb63eada4752ac5
Autor:
Holly A Jensen, Lauren E Styskal, Ryan Tasseff, Rodica P Bunaciu, Johanna Congleton, Jeffrey D Varner, Andrew Yen
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e58621 (2013)
Retinoic acid is an embryonic morphogen and dietary factor that demonstrates chemotherapeutic efficacy in inducing maturation in leukemia cells. Using HL60 model human myeloid leukemia cells, where all-trans retinoic acid (RA) induces granulocytic di
Externí odkaz:
https://doaj.org/article/eb1c498258c74967a2f933f2e89fec26
Autor:
Holly A, Jensen, Jeong, Kim
Publikováno v:
Cytometry Part A. 103:405-418
Recent advances in spectral cytometry have extended our ability to monitor immune cell subsets and activation status while simultaneously improving rare population detection. However, technical challenges in reference control selection and autofluore
Publikováno v:
FEBS Open Bio, Vol 5, Iss 1, Pp 789-800 (2015)
Transcription factors that drive non‐neoplastic myelomonocytic differentiation are well characterized but have not been systematically analyzed in the leukemic context. We investigated widely used, patient‐derived myeloid leukemia cell lines with
Externí odkaz:
https://doaj.org/article/d0666cbac1244ab8bdd815fa2f5aba0e
Autor:
Lynn Johnson, Xin Wang, Jeffrey D. Varner, Andrew Yen, Holly A. Jensen, Robert J. MacDonald, Feng Gao, Rodica P. Bunaciu
Publikováno v:
Leuk Lymphoma
In non-acute promyelotic leukemia (APL)- non myelocytic leukemia (AML), identification of a signaling signature would predict potentially actionable targets to enhance differentiation effects of all-trans-retinoic acid (RA) and make combination diffe
Publikováno v:
Cellular Signalling. 27:1666-1675
The multivariate nature of cancer necessitates multi-targeted therapy, and kinase inhibitors account for a vast majority of approved cancer therapeutics. While acute promyelocytic leukemia (APL) patients are highly responsive to retinoic acid (RA) th
Publikováno v:
FEBS Open Bio, Vol 5, Iss 1, Pp 789-800 (2015)
FEBS Open Bio
FEBS Open Bio
Highlights • We surveyed common myeloid leukemia cell lines undergoing differentiation therapy. • Lineage progression in induced leukemia cell lines differs from nonmalignant cells. • Aberrant transcription factor expression occurs in acute mye
Autor:
Jeffrey D. Varner, Ryan Tasseff, Rodica P. Bunaciu, Katharine V. Rogers, Holly A. Jensen, Wei Dai, Adithya Sagar, Andrew Yen, Johanna Congleton
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-21 (2017)
Scientific Reports
Scientific Reports
In this study, we present an effective model All-Trans Retinoic Acid (ATRA)-induced differentiation of HL-60 cells. The model describes a key architectural feature of ATRA-induced differentiation, reinforcing feedback between an ATRA-inducible signal
Autor:
Rodica P. Bunaciu, Andrew Yen, Jeffrey D. Varner, Holly A. Jensen, Lavanya G. Sayam, Johanna Congleton, Miaoqing Shen
Publikováno v:
Leukemia & Lymphoma. 52:2372-2379
All-trans retinoic acid (RA) and interferons (IFNs) have efficacy in treating certain leukemias and lymphomas, respectively, motivating interest in their mechanism of action to improve therapy. Both RA and IFNs induce interferon regulatory factor-1 (